Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Charlene Kay"'
Publikováno v:
Cancer Research. 83:PD10-09
Background: 80% of all breast cancers (BCs) are ER-positive (ER+). Not all respond to adjuvant endocrine therapy (aET) and a significant number develop endocrine resistance and recur. The basis for primary and acquired endocrine resistance is poorly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::487759f732c924813e34f37ceca59dc3
https://doi.org/10.1158/1538-7445.sabcs22-pd10-09
https://doi.org/10.1158/1538-7445.sabcs22-pd10-09
Autor:
Mark Gray, Arran K. Turnbull, James Meehan, Carlos Martínez-Pérez, Charlene Kay, Lisa Y. Pang, David J. Argyle
Publikováno v:
Frontiers in Veterinary Science, Vol 8 (2021)
Externí odkaz:
https://doaj.org/article/a79dd117347a4adc9ac16f07111d04e5
Autor:
Mark Gray, James Meehan, Arran K. Turnbull, Carlos Martínez-Pérez, Charlene Kay, Lisa Y. Pang, David J. Argyle
Publikováno v:
Frontiers in Veterinary Science, Vol 7 (2020)
Treating individual patients on the basis of specific factors, such as biomarkers, molecular signatures, phenotypes, environment, and lifestyle is what differentiates the precision medicine initiative from standard treatment regimens. Although precis
Externí odkaz:
https://doaj.org/article/6e073301f12f42c398ad3721d64f089b
Autor:
Mark Gray, Arran K. Turnbull, James Meehan, Carlos Martínez-Pérez, Charlene Kay, Lisa Y. Pang, David J. Argyle
Publikováno v:
Frontiers in Veterinary Science, Vol 7 (2020)
Research using in vitro canine mammary cancer cell lines and naturally-occurring canine mammary tumors are not only fundamental models used to advance the understanding of cancer in veterinary patients, but are also regarded as excellent translationa
Externí odkaz:
https://doaj.org/article/03478e29514d401a9b66e422bfe6cb16
Autor:
Mark Gray, James Meehan, Carlos Martínez-Pérez, Charlene Kay, Arran K. Turnbull, Linda R. Morrison, Lisa Y. Pang, David Argyle
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Despite extensive research over many decades, human breast cancer remains a major worldwide health concern. Advances in pre-clinical and clinical research has led to significant improvements in recent years in how we manage breast cancer patients. Al
Externí odkaz:
https://doaj.org/article/45c6cc0aec4d4be6b4e8d351cf46508a
Autor:
James Meehan, Mark Gray, Carlos Martínez-Pérez, Charlene Kay, Lisa Y. Pang, Jennifer A. Fraser, Amy V. Poole, Ian H. Kunkler, Simon P. Langdon, David Argyle, Arran K. Turnbull
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Radiotherapy remains an important treatment modality in nearly two thirds of all cancers, including the primary curative or palliative treatment of breast cancer. Unfortunately, largely due to tumor heterogeneity, tumor radiotherapy response rates ca
Externí odkaz:
https://doaj.org/article/f1ccff91ed624c99bba0f0182c1ae428
Autor:
Arran Turnbull, J. Michael Dixon, Lisa A. Carey, Charles M. Perou, Joel S. Parker, James Meehan, Mark Gray, Charlene Kay, Carlos Martinez-Perez, Lorna Renshaw, Xiaping He, Youli Xia
Supplementary Data from Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37bfbd200f4a48ae4b320c6fa014db22
https://doi.org/10.1158/1078-0432.22488159
https://doi.org/10.1158/1078-0432.22488159
Autor:
Simon P. Langdon, David J. Harrison, Max Hasmann, Charlene Kay, Inhwa Um, Peter Mullen, Michael Dodds, Morwenna Muir, Andrew H. Sims, Yoko Nagumo, Annelien J.M. Zweemer, Dana Faratian
Purpose: The aim of this study was to investigate the antitumor effects of HER2-directed combination therapy in ovarian cancer xenograft models to evaluate their potential. The combinations of trastuzumab and pertuzumab, and trastuzumab and aromatase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::185653759923b582f1d77952ff490cf1
https://doi.org/10.1158/1078-0432.c.6518218.v1
https://doi.org/10.1158/1078-0432.c.6518218.v1
Autor:
Arran Turnbull, J. Michael Dixon, Lisa A. Carey, Charles M. Perou, Joel S. Parker, James Meehan, Mark Gray, Charlene Kay, Carlos Martinez-Perez, Lorna Renshaw, Xiaping He, Youli Xia
Purpose:Endocrine therapy resistance (ETR) remains the greatest challenge in treating patients with hormone receptor–positive breast cancer. We set out to identify molecular mechanisms underlying ETR through in-depth genomic analysis of breast tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::967eefeb9482f9d4ee595afe3677d5b2
https://doi.org/10.1158/1078-0432.c.6532650.v1
https://doi.org/10.1158/1078-0432.c.6532650.v1
Autor:
Simon P. Langdon, David J. Harrison, Max Hasmann, Charlene Kay, Inhwa Um, Peter Mullen, Michael Dodds, Morwenna Muir, Andrew H. Sims, Yoko Nagumo, Annelien J.M. Zweemer, Dana Faratian
Supplementary Figures S1-S4 from Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::197c490eaaf6a33b30fbf92fcd13bcd5
https://doi.org/10.1158/1078-0432.22441030.v1
https://doi.org/10.1158/1078-0432.22441030.v1